Lue HW - Search Results

1

Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade.

Lue HW, Podolak J, Kolahi K, Cheng L, Rao S, Garg D, Xue CH, Rantala JK, Tyner JW, Thornburg KL, Martinez-Acevedo A, Liu JJ, Amling CL, Truillet C, Louie SM, Anderson KE, Evans MJ, O'Donnell VB, Nomura DK, Drake JM, Ritz A, Thomas GV. Lue HW, et al. Genes Dev. 2017 Oct 15;31(20):2067-2084. doi: 10.1101/gad.305292.117. Epub 2017 Nov 14. Genes Dev. 2017. PMID: 29138276 Free PMC article.

2

Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.

Lue HW, Cole B, Rao SA, Podolak J, Van Gaest A, King C, Eide CA, Wilmot B, Xue C, Spellman PT, Heiser LM, Tyner JW, Thomas GV. Lue HW, et al. Oncotarget. 2015 Dec 29;6(42):44675-87. doi: 10.18632/oncotarget.5971. Oncotarget. 2015. PMID: 26625308 Free PMC article.

3

Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma.

Lue HW, Derrick DS, Rao S, Van Gaest A, Cheng L, Podolak J, Lawson S, Xue C, Garg D, White R 3rd, Ryan CW, Drake JM, Ritz A, Heiser LM, Thomas GV. Lue HW, et al. Cell Rep Med. 2021 May 7;2(5):100267. doi: 10.1016/j.xcrm.2021.100267. eCollection 2021 May 18. Cell Rep Med. 2021. PMID: 34095877 Free PMC article.

4

Multi-Omics Analyses Detail Metabolic Reprogramming in Lipids, Carnitines, and Use of Glycolytic Intermediates between Prostate Small Cell Neuroendocrine Carcinoma and Prostate Adenocarcinoma.

Gao B, Lue HW, Podolak J, Fan S, Zhang Y, Serawat A, Alumkal JJ, Fiehn O, Thomas GV. Gao B, et al. Among authors: lue hw. Metabolites. 2019 Apr 26;9(5):82. doi: 10.3390/metabo9050082. Metabolites. 2019. PMID: 31035489 Free PMC article.

5

Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer.

Podolak J, Eilers K, Newby T, Slottke R, Tucker E, Olson SB, Lue HW, Youngren J, Aggarwal R, Small EJ, Graff JN, Alumkal JJ, Beer TM, Thomas GV. Podolak J, et al. Among authors: lue hw. Oncotarget. 2017 Mar 13;8(42):71447-71455. doi: 10.18632/oncotarget.16169. eCollection 2017 Sep 22. Oncotarget. 2017. PMID: 29069718 Free PMC article.

6

Beta2-microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells.

Huang WC, Havel JJ, Zhau HE, Qian WP, Lue HW, Chu CY, Nomura T, Chung LW. Huang WC, et al. Among authors: lue hw. Clin Cancer Res. 2008 Sep 1;14(17):5341-7. doi: 10.1158/1078-0432.CCR-08-0793. Clin Cancer Res. 2008. PMID: 18765525 Free PMC article.

7

Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model.

Zhau HE, Odero-Marah V, Lue HW, Nomura T, Wang R, Chu G, Liu ZR, Zhou BP, Huang WC, Chung LW. Zhau HE, et al. Among authors: lue hw. Clin Exp Metastasis. 2008;25(6):601-10. doi: 10.1007/s10585-008-9183-1. Epub 2008 Jun 6. Clin Exp Metastasis. 2008. PMID: 18535913 Free PMC article.

8

LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling.

Lue HW, Yang X, Wang R, Qian W, Xu RZ, Lyles R, Osunkoya AO, Zhou BP, Vessella RL, Zayzafoon M, Liu ZR, Zhau HE, Chung LW. Lue HW, et al. PLoS One. 2011;6(11):e27720. doi: 10.1371/journal.pone.0027720. Epub 2011 Nov 16. PLoS One. 2011. PMID: 22110740 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters